Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):723–726. doi: 10.1038/bjc.1992.152

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

S Négrier 1, A Mercatello 1, M Bret 1, P Thiesse 1, J Y Blay 1, B Coronel 1, Y Merrouche 1, R Oskam 1, C R Franks 1, M Clavel 1, et al.
PMCID: PMC1977403  PMID: 1586600

Abstract

The present study was designed in order to evaluate the response rate and the toxicity of continuous infusion of Interleukin 2 (IL2) in patients over 65 with metastatic renal cell carcinoma. Twenty-five patients, median age 69 (range 65-77), without any prior systemic anticancer therapy received a continuous infusion of IL2 at a dose of 18 x 10(6) iu m-2 d-1 for 2 periods of 5 days separated by a 6 day break. Toxicity was not different compared with younger patients (e.g. fever, hypotension, rise in creatinine level), except for cardiac toxicity which was of great concern. Despite normal cardiac tests prior to inclusion into the study, abnormalities of the cardiac rhythm ranging from tachycardia to ventricular extrasystoles occurred in 44% of the patients and IL2 cardiac toxicity was responsible for one toxic death. Three objective responses, i.e. one partial and two complete persistent responses, were seen in 22 evaluable patients. Thus, if age does not seem to modify the potential for response to IL2 therapy, cardiac toxicity appears as a limiting factor for intravenous schedules of IL2.

Full text

PDF
723

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  2. Bergerat J. P., Herbrecht R., Dufour P., Jacqmin D., Bollack C., Prevot G., Bailly G., de Garis S., Juraschek F., Oberling F. Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer. 1988 Dec 1;62(11):2320–2324. doi: 10.1002/1097-0142(19881201)62:11<2320::aid-cncr2820621111>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  3. Blay J. Y., Favrot M. C., Negrier S., Combaret V., Chouaib S., Mercatello A., Kaemmerlen P., Franks C. R., Philip T. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res. 1990 Apr 15;50(8):2371–2374. [PubMed] [Google Scholar]
  4. Droz J. P., Theodore C., Ghosn M., Lupera H., Piot G., De Forges A., Klink M., Rouesse J., Amiel J. L. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy. Semin Surg Oncol. 1988;4(2):97–99. [PubMed] [Google Scholar]
  5. Elson P. J., Witte R. S., Trump D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988 Dec 15;48(24 Pt 1):7310–7313. [PubMed] [Google Scholar]
  6. Finney R. An evaluation of postoperative radiotherapy in hypernephroma treatment--a clinical trial. Cancer. 1973 Dec;32(6):1332–1340. doi: 10.1002/1097-0142(197312)32:6<1332::aid-cncr2820320607>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  7. Fisher R. I., Coltman C. A., Jr, Doroshow J. H., Rayner A. A., Hawkins M. J., Mier J. W., Wiernik P., McMannis J. D., Weiss G. R., Margolin K. A. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr;108(4):518–523. doi: 10.7326/0003-4819-108-4-518. [DOI] [PubMed] [Google Scholar]
  8. Holland J. M. Proceedings: Cancer of the kidney--natural history and staging. Cancer. 1973 Nov;32(5):1030–1042. doi: 10.1002/1097-0142(197311)32:5<1030::aid-cncr2820320502>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  9. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Nora R., Abrams J. S., Tait N. S., Hiponia D. J., Silverman H. J. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989 Jan 4;81(1):59–63. doi: 10.1093/jnci/81.1.59. [DOI] [PubMed] [Google Scholar]
  11. Philip T., Mercatello A., Negrier S., Philip I., Rebattu P., Kaemmerlin P., Gaspard M., Tognier E., Combaret V., Bijmann J. T. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev. 1989 Jun;16 (Suppl A):91–104. doi: 10.1016/0305-7372(89)90028-5. [DOI] [PubMed] [Google Scholar]
  12. Quesada J. R., Rios A., Swanson D., Trown P., Gutterman J. U. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985 Nov;3(11):1522–1528. doi: 10.1200/JCO.1985.3.11.1522. [DOI] [PubMed] [Google Scholar]
  13. Ritchie A. W., deKernion J. B. The natural history and clinical features of renal carcinoma. Semin Nephrol. 1987 Jun;7(2):131–139. [PubMed] [Google Scholar]
  14. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  15. Siegel J. P., Puri R. K. Interleukin-2 toxicity. J Clin Oncol. 1991 Apr;9(4):694–704. doi: 10.1200/JCO.1991.9.4.694. [DOI] [PubMed] [Google Scholar]
  16. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES